NASDAQ:OCS Oculis (OCS) Stock Price, News & Analysis $17.18 +0.01 (+0.06%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Oculis Stock (NASDAQ:OCS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oculis alerts:Sign Up Key Stats Today's Range$17.04▼$17.5850-Day Range$11.85▼$17.1752-Week Range$9.05▼$17.58Volume44,499 shsAverage Volume35,543 shsMarket Capitalization$695.86 millionP/E RatioN/ADividend YieldN/APrice Target$29.20Consensus RatingBuy Company OverviewOculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Read More… The real reason Elon is fully endorsing Trump (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, Oculis Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks38th Percentile Overall ScoreOCS MarketRank™: Oculis scored higher than 38% of companies evaluated by MarketBeat, and ranked 770th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOculis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOculis has only been the subject of 1 research reports in the past 90 days.Read more about Oculis' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oculis are expected to decrease in the coming year, from ($2.19) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oculis is -8.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oculis is -8.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOculis has a P/B Ratio of 5.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oculis' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.18% of the float of Oculis has been sold short.Short Interest Ratio / Days to CoverOculis has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oculis has recently increased by 133.68%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOculis does not currently pay a dividend.Dividend GrowthOculis does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.18% of the float of Oculis has been sold short.Short Interest Ratio / Days to CoverOculis has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oculis has recently increased by 133.68%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.55 News SentimentOculis has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Oculis this week, compared to 2 articles on an average week.Search Interest4 people have searched for OCS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oculis insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 22.30% of the stock of Oculis is held by institutions.Read more about Oculis' insider trading history. Receive OCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter. Email Address OCS Stock News HeadlinesOculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39%October 31 at 1:17 AM | finance.yahoo.comOculis Holding Gains ‘Buy’ Rating Amid Promising Clinical Trial Advancements and Pipeline PotentialOctober 23, 2024 | markets.businessinsider.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.October 31, 2024 | Weiss Ratings (Ad)Oculis accelerates patient enrollment for both Phase 3 DIAMOND trialsOctober 22, 2024 | markets.businessinsider.comOculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program CommitteesOctober 21, 2024 | globenewswire.comOculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program CommitteesOctober 21, 2024 | globenewswire.comOculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024October 15, 2024 | globenewswire.comOculis Announces Appointment of Daniel S. Char as Chief Legal OfficerOctober 2, 2024 | globenewswire.comSee More Headlines OCS Stock Analysis - Frequently Asked Questions How have OCS shares performed this year? Oculis' stock was trading at $11.23 at the start of the year. Since then, OCS stock has increased by 53.0% and is now trading at $17.18. View the best growth stocks for 2024 here. How were Oculis' earnings last quarter? Oculis Holding AG (NASDAQ:OCS) posted its quarterly earnings results on Tuesday, August, 27th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.13. The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. Oculis had a negative net margin of 7,679.05% and a negative trailing twelve-month return on equity of 61.33%. Who are Oculis' major shareholders? Top institutional shareholders of Oculis include abrdn plc (2.03%). How do I buy shares of Oculis? Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Oculis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oculis investors own include SoFi Technologies (SOFI), Meta Platforms (META), Bitdeer Technologies Group (BTDR), Purpose Bitcoin ETF (BTCC.B), Booz Allen Hamilton (BAH), Broadcom (AVGO) and Atara Biotherapeutics (ATRA). Company Calendar Last Earnings8/27/2024Today10/31/2024Next Earnings (Estimated)11/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCS CUSIPN/A CIK1953530 Webwww.oculis.com Phone41-21-711-3970FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$29.20 High Stock Price Target$37.00 Low Stock Price Target$20.00 Potential Upside/Downside+70.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,920,000.00 Net Margins-7,679.05% Pretax MarginN/A Return on Equity-61.33% Return on Assets-49.91% Debt Debt-to-Equity Ratio0.01 Current Ratio5.27 Quick Ratio5.27 Sales & Book Value Annual Sales$980,000.00 Price / Sales708.41 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book5.97Miscellaneous Outstanding Shares40,504,000Free FloatN/AMarket Cap$694.24 million OptionableNot Optionable Beta0.30 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:OCS) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.